Target
ATR
6 products, 8 indications
Indications
Platinum-sensitive recurrent ovarian carcinoma (1 products)
high grade serous ovarian carcinoma (1 products)
metastatic melanoma (1 products)
ovarian cancer (1 products)
platinum-resistant high-grade serous ovarian cancer (1 products)
Platinum-resistant recurrent ovarian carcinoma (1 products)
Metastatic Castration-Resistant Prostate Cancer (1 products)
TP53-mutated gastric and gastro-esophageal junction adenocarcinoma (1 products)
Loading...
2 drugs
2 abstracts
Abstract
Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-sensitive epithelial ovarian cancer (cohort A).Org: AstraZeneca, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Dana-Farber Cancer Institute,
Abstract
Pharmacodynamic (PD) and immunophenotyping analyses of ATR inhibitor (ATRi) tuvusertib + ATM inhibitor (ATMi) lartesertib in a phase Ib study in patients with advanced unresectable solid tumors.Org: New Experimental Therapeutics (NEXT), Merck Serono Ltd.,
Drug
ceralasertibDrug
berzosertib